Esoteric Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Esoteric Testing Market is Segmented by Test Specialty (Endocrinology, Infectious Disease, Oncology, Neurology, and More), Technology (Flow Cytometry, Chemiluminescence Immunoassay, Mass Spectrometry, Radio Immunoassay, and More), Sample Type (Blood and More), End User (Hospitals and Clinics and More), and Geography (North America, Europe, Asia Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Esoteric Testing Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Esoteric Testing Market with other markets in Healthcare Industry

Esoteric Testing Market Analysis by Mordor Intelligence

The esoteric testing market is valued at USD 27.21 billion in 2025 and is forecast to reach USD 47.26 billion by 2030, expanding at an 11.67% CAGR. Demand accelerates as chronic disease prevalence rises, next-generation sequencing (NGS) becomes routine, and hospitals outsource complex assays to reference laboratories. New FDA rules classifying laboratory-developed tests as medical devices introduce cost but ultimately set clear quality standards that can boost global credibility [1]U.S. Food and Drug Administration, “Final Rule: Medical Devices; Laboratory Developed Tests,” fda.gov . Automation investments, declining sequencing costs, and payer support for high-impact panels further reinforce growth momentum.

Key Report Takeaways

  • By test specialty, endocrinology led with 27.22% of the esoteric testing market share in 2024; oncology tests are projected to grow at a 12.38% CAGR through 2030.  
  • By technology, chemiluminescence immunoassay held 26.91% of the esoteric testing market size in 2024, while NGS platforms are advancing at a 12.29% CAGR to 2030.  
  • By sample type, blood accounted for 48.41% of the esoteric testing market size in 2024; saliva specimens record the fastest 12.44% CAGR to 2030.  
  • By end user, hospitals and clinics controlled 51.98% of the esoteric testing market size in 2024, whereas diagnostics laboratories expand at a 12.54% CAGR to 2030.  
  • By geography, North America controlled 41.94% of the esoteric testing market size in 2024, whereas Asia-Pacific expand at a 12.31% CAGR to 2030.  

Segment Analysis

By Test Specialty: Oncology Drives Precision Medicine Growth

Oncology’s 12.38% CAGR makes it the fastest-moving specialty because liquid biopsy and comprehensive genomic profiling guide targeted treatments. FoundationOne CDx and Guardant Shield approvals show regulators view broad tumor panels as clinically essential. Endocrinology remains the revenue anchor, capturing 27.22% of the esoteric testing market size in 2024 through insulin, HbA1c, and thyroid assays.

Clinical focus continues to shift from high-volume thyroid testing to sophisticated biomarker suites that stratify cancer risk. Infectious-disease, neurology, and immunology segments benefit from AI-driven interpretation, but oncology captures the spotlight as payers reimburse for tests that match therapy to mutation, shortening hospital stays and improving outcomes.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: NGS Platforms Reshape Molecular Diagnostics

Sequencing costs have fallen below USD 200 per genome, and regulatory green lights for multi-gene panels propel NGS to a 12.29% CAGR. Illumina’s kit-based oncology panel gained FDA clearance, giving smaller labs plug-and-play capability. Chemiluminescence immunoassay remains dominant with a 26.91% esoteric testing market share due to its scalable menu across endocrinology and infectious disease.

Flow cytometry broadens from hematology into immune profiling, while mass spectrometry moves from research to routine through automated sample prep. Although real-time PCR sustains infectious-disease demand, ELISA and radio-immunoassay fade as labs consolidate around faster, multiplexed options.

By Sample Type: Saliva Testing Gains Non-Invasive Advantage

Blood retained 48.41% of the esoteric testing market size in 2024 thanks to clinician familiarity and robust reference ranges. Yet saliva registers the strongest 12.44% CAGR as patients prefer painless self-collection and telehealth expands kit distribution. 

COVID-19 catalyzed saliva acceptance; now hormone, pharmacogenomic, and viral-load assays routinely run on spit specimens. Urine and cerebrospinal fluid serve niche metabolic and neurological needs, but logistics, not clinical value, restrict wider adoption.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Diagnostics Laboratories Lead Specialization Trend

Hospitals delivered 51.98% of revenue in 2024, yet reference labs grow faster at 12.54% CAGR as health systems outsource complexity. Staffing gaps—80% of microbiology labs report vacancies—push work to high-throughput centers with robotics.

Academic institutes pilot novel assays, then license them to commercial labs. Consolidators such as LabCorp snapped up BioReference oncology assets to broaden menus nationally, signaling that size plus specialization beats geography alone.

Geography Analysis

North America commanded 41.94% revenue in 2024. Medicare’s MolDX pathway speeds coverage for molecular tests, and the region’s payer mix supports premium pricing. Ongoing mergers—including Quest Diagnostics’ takeover of LifeLabs—bundle logistics networks with AI-enabled result portals, reinforcing regional dominance.

Asia-Pacific is the fastest-growing region at a 12.31% CAGR. China’s regulator cleared 228 new drugs in 2024, 92 with companion diagnostics, sparking hospital demand for multi-gene tests. Indian chains such as Dr. Lal PathLabs push into tier-3 cities while Molbio Diagnostics readies a USD 265 million IPO to fund molecular expansion. Mobile health platforms link rural clinics to reference labs, shortening sample-to-result cycles.

Europe posts stable single-digit gains. Cross-border lab alliances streamline sample routing, and sustainability mandates spur demand for environmental toxicology panels. Eurofins reported EUR 6.951 billion revenue in 2024 after 31 acquisitions, highlighting a buy-and-build model that keeps menu breadth ahead of regional peers. Latin America and Middle East & Africa advance steadily as private insurers widen coverage, though infrastructure gaps and import duties temper immediate scale.

Esoteric Testing Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market concentration is moderate. LabCorp, Quest Diagnostics, and Eurofins together control roughly one-third of global revenue, aided by nationwide logistics, regulatory muscle, and multi-omics menus. Each firm inked multiple acquisitions in 2024; LabCorp’s purchase of BioReference assets broadened oncology reach, while Eurofins picked up 18 start-ups to boost regional depth.

Specialist players carve niches. ARUP Laboratories secured the first FDA-authorized AAV5 DetectCDx for gene-therapy monitoring, underscoring academic labs’ role in pioneering new categories. Caris Life Sciences combined whole-exome and transcriptome sequencing in its MI Cancer Seek test, winning approval for pan-tumor profiling.

Technology partnerships proliferate. AI vendors integrate with LIMS software to flag contamination, while robotics firms supply modular aliquoting lines that raise throughput without adding staff. Workforce shortages create barriers to entry, yet cloud-hosted analysis pipelines let smaller labs run sophisticated panels without building local bioinformatics teams.

Esoteric Testing Industry Leaders

  1. bioMontr Labs

  2. Quest Diagnostics

  3. Kindstar Globalgene Technology, Inc.

  4. H.U. Group Holdings, Inc.

  5. Laboratory Corporation of America Holdings

  6. *Disclaimer: Major Players sorted in no particular order
Esoteric Testing Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: ARUP Laboratories extended its AI parasitology system to wet-mount slides, recording five-fold sensitivity gains.
  • March 2025: LabCorp bought BioReference Health’s oncology testing assets, deepening nationwide cancer-genomics coverage.
  • January 2025: bioMérieux closed its EUR 111 million acquisition of SpinChip Diagnostics, adding 10-minute whole-blood immunoassay capability.
  • November 2024: Caris Life Sciences obtained FDA approval for MI Cancer Seek, the first assay to combine whole-exome and whole-transcriptome sequencing for solid tumors.

Table of Contents for Esoteric Testing Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic & Complex Diseases
    • 4.2.2 Growing Demand for Rare-Disease Diagnostics
    • 4.2.3 Advances In Molecular & Multi-Omics Platforms
    • 4.2.4 Increased R&D Funding and Lab Automation
    • 4.2.5 Value-Based Reimbursement Favouring High-Impact Esoteric Panels
    • 4.2.6 Digital E-Ordering Portals Expanding Test Accessibility
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory & Compliance Requirements
    • 4.3.2 High Per-Test Cost in Price-Sensitive Economies
    • 4.3.3 Shortage Of Highly Skilled Laboratory Personnel
    • 4.3.4 Data-Integration Hurdles for Multi-Omics Reports
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porters Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Test Specialty
    • 5.1.1 Endocrinology
    • 5.1.2 Infectious Disease
    • 5.1.3 Oncology
    • 5.1.4 Neurology
    • 5.1.5 Immunology
    • 5.1.6 Genetics
    • 5.1.7 Others
  • 5.2 By Technology
    • 5.2.1 Flow Cytometry
    • 5.2.2 Chemiluminescence Immunoassay
    • 5.2.3 Mass Spectrometry
    • 5.2.4 Real-time PCR
    • 5.2.5 Next-Generation Sequencing (NGS)
    • 5.2.6 ELISA
    • 5.2.7 Radio Immunoassay
    • 5.2.8 Others
  • 5.3 By Sample Type
    • 5.3.1 Blood
    • 5.3.2 Urine
    • 5.3.3 Saliva
    • 5.3.4 Cerebrospinal Fluid (CSF)
    • 5.3.5 Others
  • 5.4 By End User
    • 5.4.1 Hospitals and Clinics
    • 5.4.2 Diagnostics Laboratories
    • 5.4.3 Academic and Research Institutes
    • 5.4.4 Others
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Laboratory Corporation of America Holdings
    • 6.3.2 Quest Diagnostics Incorporated
    • 6.3.3 Sonic Healthcare Limited
    • 6.3.4 Eurofins Scientific SE
    • 6.3.5 Mayo Clinic Laboratories
    • 6.3.6 ARUP Laboratories
    • 6.3.7 Kindstar Global Gene Technology
    • 6.3.8 Fulgent Genetics
    • 6.3.9 Grifols, S.A.
    • 6.3.10 H.U. Group Holdings, Inc.
    • 6.3.11 Nordic Laboratories
    • 6.3.12 OPKO Health (BioReference)
    • 6.3.13 SYNLAB AG
    • 6.3.14 Sonic Reference Labs (USA)
    • 6.3.15 ACM Global Laboratories
    • 6.3.16 Charles River Laboratories
    • 6.3.17 Exact Sciences Corporation
    • 6.3.18 Invitae Corporation
    • 6.3.19 Beijing Genomics Institute (BGI)
    • 6.3.20 Neuberg Diagnostics

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Esoteric Testing Market Report Scope

As per the scope of the report, esoteric testing is used for analyzing and detecting rare substances and molecules. 

The esoteric testing market is segmented by test type, technology, and geography. By test type, the market is segmented into endocrinology, infectious disease, oncology, neurology, toxicology, and others. By technology, the market is segmented into flow cytometry, chemiluminescence immunoassay, mass spectrometry, radio immunoassay, and others. By geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.

By Test Specialty Endocrinology
Infectious Disease
Oncology
Neurology
Immunology
Genetics
Others
By Technology Flow Cytometry
Chemiluminescence Immunoassay
Mass Spectrometry
Real-time PCR
Next-Generation Sequencing (NGS)
ELISA
Radio Immunoassay
Others
By Sample Type Blood
Urine
Saliva
Cerebrospinal Fluid (CSF)
Others
By End User Hospitals and Clinics
Diagnostics Laboratories
Academic and Research Institutes
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Test Specialty
Endocrinology
Infectious Disease
Oncology
Neurology
Immunology
Genetics
Others
By Technology
Flow Cytometry
Chemiluminescence Immunoassay
Mass Spectrometry
Real-time PCR
Next-Generation Sequencing (NGS)
ELISA
Radio Immunoassay
Others
By Sample Type
Blood
Urine
Saliva
Cerebrospinal Fluid (CSF)
Others
By End User
Hospitals and Clinics
Diagnostics Laboratories
Academic and Research Institutes
Others
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected value of the esoteric testing market by 2030?

The esoteric testing market is expected to reach USD 47.26 billion by 2030.

Which test specialty is growing the fastest?

Oncology testing leads growth with a 12.38% CAGR through 2030, driven by liquid biopsy and comprehensive genomic profiling approvals.

Why are saliva-based assays gaining popularity?

Saliva sampling is non-invasive and supports at-home collection, fueling a 12.44% CAGR for saliva tests within the esoteric testing market.

How will the new FDA LDT rule affect laboratories?

Labs must meet medical-device standards, adding compliance costs of up to USD 3.56 billion industry-wide but ultimately ensuring higher quality and global credibility.

Which region offers the highest growth potential?

Asia-Pacific records the fastest 12.31% CAGR, buoyed by China’s companion-diagnostic approvals and expanding molecular-testing infrastructure.

What technology holds the largest esoteric testing market share today?

Chemiluminescence immunoassay leads with 26.91% of 2024 revenue, though NGS platforms are growing the quickest.

Esoteric Testing Market Report Snapshots